Ketamine has been making headlines for years, from the death of actor Matthew Perry to Elon Musk's reported microdosing, to its portrayal in Hulu's "The Secret Lives of Mormon Wives." ...

Atai Life Sciences is making incremental progress towards opening door for a first psychedelic treatment for depression. Read ...

Atai Life Sciences’ psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of the biotech’s planned merger with mental health company ...

Cosmo Feilding Mellen – currently Beckley's chief executive, who is slated to serve as chief strategy officer of the merged ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

None have been approved by the Food and Drug Administration so far, though in 2019, Johnson & Johnson received FDA permission ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

Dr. Miers said Bryan Health is the only hospital in Lincoln that offers Spravato and the only hospital that offers ElectroConvulsive therapy, also known as ‘electric shock therapy’. To learn ...

While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s ...

Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a ...

Compass Pathways' psilocybin-based depression therapy reduced the severity of symptoms in a closely watched study, but shares of the biotech firm plunged more than 46% to a record low on Monday as the ...